Laura B. Goddard

Array ( [id] => 18117768 [patent_doc_number] => 11549150 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-01-10 [patent_title] => Treatment of cancers having mutations of the PIK3CA gene [patent_app_type] => utility [patent_app_number] => 16/595055 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 5 [patent_no_of_words] => 6772 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16595055 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15960601 [patent_doc_number] => 20200164052 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => HER2 ANTIGENIC POLYPEPTIDE COMPOSITIONS, AND METHODS FOR THEIR USE IN TREATMENT AND PREVENTION OF CARCINOMAS [patent_app_type] => utility [patent_app_number] => 16/594436 [patent_app_country] => US [patent_app_date] => 2019-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18740 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16594436 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15435515 [patent_doc_number] => 20200031941 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/591394 [patent_app_country] => US [patent_app_date] => 2019-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 53690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 216 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16591394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198634 [patent_doc_number] => 20210338728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS [patent_app_type] => utility [patent_app_number] => 17/279938 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17198634 [patent_doc_number] => 20210338728 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-04 [patent_title] => METHODS AND COMPOSITIONS FOR THE EXPANSION AND USE OF ALLOGENEIC GAMMA/DELTA-T CELLS [patent_app_type] => utility [patent_app_number] => 17/279938 [patent_app_country] => US [patent_app_date] => 2019-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17279938 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17776598 [patent_doc_number] => 20220242947 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-08-04 [patent_title] => PROVASOPRESSIN ANTAGONISTS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 16/575911 [patent_app_country] => US [patent_app_date] => 2019-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22997 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16575911 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17412825 [patent_doc_number] => 20220047729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-17 [patent_title] => MUTANT VARIANTS OF PD-1 RECEPTOR WITH SELECTIVE BINDING TO PD-L1 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/278869 [patent_app_country] => US [patent_app_date] => 2019-09-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7257 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17278869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15590389 [patent_doc_number] => 20200071729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-05 [patent_title] => CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSION [patent_app_type] => utility [patent_app_number] => 16/570827 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68071 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16570827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18012146 [patent_doc_number] => 11504420 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => AGGF1 immunogenic compositions [patent_app_type] => utility [patent_app_number] => 16/571008 [patent_app_country] => US [patent_app_date] => 2019-09-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8463 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16571008 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19792204 [patent_doc_number] => 12233127 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-25 [patent_title] => Human monoclonal antibodies to a new universal influenza A hemagglutinin head domain epitope [patent_app_type] => utility [patent_app_number] => 17/270115 [patent_app_country] => US [patent_app_date] => 2019-08-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 52 [patent_figures_cnt] => 48 [patent_no_of_words] => 65530 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 74 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17270115 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16932477 [patent_doc_number] => 20210198366 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-07-01 [patent_title] => B7-H7-BINDING AGENTS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/269635 [patent_app_country] => US [patent_app_date] => 2019-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49775 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -86 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17269635 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15212823 [patent_doc_number] => 20190369098 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-05 [patent_title] => DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCER [patent_app_type] => utility [patent_app_number] => 16/545177 [patent_app_country] => US [patent_app_date] => 2019-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101565 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -174 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16545177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15451393 [patent_doc_number] => 20200038520 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/544625 [patent_app_country] => US [patent_app_date] => 2019-08-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 23231 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -44 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16544625 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15254193 [patent_doc_number] => 20190375830 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-12 [patent_title] => ANTIBODY AND ANTIGEN-BINDING FRAGMENT COMPOSITIONS TARGETING CELL SURFACE ANTIGENS IN TUMORS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 16/533937 [patent_app_country] => US [patent_app_date] => 2019-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13181 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 82 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15931209 [patent_doc_number] => 20200157238 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-21 [patent_title] => PERTUZUMAB VARIANTS AND EVALUATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/533488 [patent_app_country] => US [patent_app_date] => 2019-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20306 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16533488 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15363657 [patent_doc_number] => 20200017593 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-16 [patent_title] => METHOD OF PRODUCING ANTIBODIES WITH N-GLYCOSIDE-LINKED SUGAR CHAINS LACKING FUCOSYLATION [patent_app_type] => utility [patent_app_number] => 16/517776 [patent_app_country] => US [patent_app_date] => 2019-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22607 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16517776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15454513 [patent_doc_number] => 20200040081 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-06 [patent_title] => Anti-CD112R Compositions and Methods [patent_app_type] => utility [patent_app_number] => 16/516613 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35458 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16516613 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17627321 [patent_doc_number] => 20220162336 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-05-26 [patent_title] => TREATMENT OF LYMPHATIC METASTASES [patent_app_type] => utility [patent_app_number] => 17/261958 [patent_app_country] => US [patent_app_date] => 2019-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27969 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17261958 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15117251 [patent_doc_number] => 20190345258 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-11-14 [patent_title] => PERTUZUMAB VARIANTS AND EVALUATION THEREOF [patent_app_type] => utility [patent_app_number] => 16/510287 [patent_app_country] => US [patent_app_date] => 2019-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20318 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16510287 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18171782 [patent_doc_number] => 11571475 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2023-02-07 [patent_title] => Anti-CD70 and BCR-ABL inhibitor combination therapy [patent_app_type] => utility [patent_app_number] => 16/506546 [patent_app_country] => US [patent_app_date] => 2019-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 14 [patent_no_of_words] => 19693 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16506546 [rel_patent_id] =>[rel_patent_doc_number] =>)